Literature DB >> 28024403

Genetic Algorithm Managed Peptide Mutant Screening: Optimizing Peptide Ligands for Targeted Receptor Binding.

Matthew D King1, Thomas Long1, Timothy Andersen1, Owen M McDougal1.   

Abstract

This study demonstrates the utility of genetic algorithms to search exceptionally large and otherwise intractable mutant libraries for sequences with optimal binding affinities for target receptors. The Genetic Algorithm Managed Peptide Mutant Screening (GAMPMS) program was used to search an α-conotoxin (α-CTx) MII mutant library of approximately 41 billion possible peptide sequences for those exhibiting the greatest binding affinity for the α3β2-nicotinic acetylcholine receptor (nAChR) isoform. A series of top resulting peptide ligands with high sequence homology was obtained, with each mutant having an estimated ΔGbind approximately double that of the potent native α-CTx MII ligand. A consensus sequence from the top GAMPMS results was subjected to more rigorous binding free energy calculations by molecular dynamics and compared to α-CTx MII and other related variants for binding with α3β2-nAChR. In this study, the efficiency of GAMPMS to substantially reduce the sample population size through evolutionary selection criteria to produce ligands with higher predicted binding affinity is demonstrated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28024403      PMCID: PMC5367625          DOI: 10.1021/acs.jcim.6b00095

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  42 in total

1.  Consideration of molecular weight during compound selection in virtual target-based database screening.

Authors:  Yongping Pan; Niu Huang; Sam Cho; Alexander D MacKerell
Journal:  J Chem Inf Comput Sci       Date:  2003 Jan-Feb

2.  A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations.

Authors:  Yong Duan; Chun Wu; Shibasish Chowdhury; Mathew C Lee; Guoming Xiong; Wei Zhang; Rong Yang; Piotr Cieplak; Ray Luo; Taisung Lee; James Caldwell; Junmei Wang; Peter Kollman
Journal:  J Comput Chem       Date:  2003-12       Impact factor: 3.376

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Exploring the helix-coil transition via all-atom equilibrium ensemble simulations.

Authors:  Eric J Sorin; Vijay S Pande
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

5.  Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.

Authors:  D M Morens; J W Davis; A Grandinetti; G W Ross; J S Popper; L R White
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  GAMPMS: Genetic algorithm managed peptide mutant screening.

Authors:  Thomas Long; Owen M McDougal; Tim Andersen
Journal:  J Comput Chem       Date:  2015-05-15       Impact factor: 3.376

7.  Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.

Authors:  Tanuja Bordia; Sharon R Grady; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2007-04-04       Impact factor: 4.436

Review 8.  The M-superfamily of conotoxins: a review.

Authors:  Reed B Jacob; Owen M McDougal
Journal:  Cell Mol Life Sci       Date:  2009-08-25       Impact factor: 9.261

9.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.

Authors:  J Michael McIntosh; Layla Azam; Sarah Staheli; Cheryl Dowell; Jon M Lindstrom; Alexander Kuryatov; James E Garrett; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

10.  Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.

Authors:  Outi Salminen; Jennifer A Drapeau; J Michael McIntosh; Allan C Collins; Michael J Marks; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2007-03-06       Impact factor: 4.436

View more
  6 in total

1.  Discovery of peptide ligands through docking and virtual screening at nicotinic acetylcholine receptor homology models.

Authors:  Abba E Leffler; Alexander Kuryatov; Henry A Zebroski; Susan R Powell; Petr Filipenko; Adel K Hussein; Juliette Gorson; Anna Heizmann; Sergey Lyskov; Richard W Tsien; Sébastien F Poget; Annette Nicke; Jon Lindstrom; Bernardo Rudy; Richard Bonneau; Mandë Holford
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

2.  [β2-nicotinic acetylcholine receptor promotes development of GABAA receptors in mouse hippocampal CA1 and CA3 pyramidal neurons].

Authors:  Chao Zheng; Yan Huang; Huanhuan Zhang; Yingying Zha; Mengya Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-08-30

3.  SPIDR: small-molecule peptide-influenced drug repurposing.

Authors:  Matthew D King; Thomas Long; Daniel L Pfalmer; Timothy L Andersen; Owen M McDougal
Journal:  BMC Bioinformatics       Date:  2018-04-16       Impact factor: 3.169

Review 4.  Mutagenesis of α-Conotoxins for Enhancing Activity and Selectivity for Nicotinic Acetylcholine Receptors.

Authors:  Matthew W Turner; Leanna A Marquart; Paul D Phillips; Owen M McDougal
Journal:  Toxins (Basel)       Date:  2019-02-13       Impact factor: 4.546

5.  Qualitative Assay to Detect Dopamine Release by Ligand Action on Nicotinic Acetylcholine Receptors.

Authors:  Leanna A Marquart; Matthew W Turner; Owen M McDougal
Journal:  Toxins (Basel)       Date:  2019-11-20       Impact factor: 4.546

6.  Ribbon α-Conotoxin KTM Exhibits Potent Inhibition of Nicotinic Acetylcholine Receptors.

Authors:  Leanna A Marquart; Matthew W Turner; Lisa R Warner; Matthew D King; James R Groome; Owen M McDougal
Journal:  Mar Drugs       Date:  2019-11-28       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.